Published in J Transl Med on September 04, 2014
Autologous Dendritic Cell Vaccination in Mesothelioma (MESODEC) | NCT02649829
Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells. Sci Rep (2016) 0.76
Biologic therapy and gene therapy in the multimodality treatment of malignant pleural mesothelioma. Ann Transl Med (2015) 0.75
Transient Treg depletion enhances therapeutic anti-cancer vaccination. Immun Inflamm Dis (2016) 0.75
Tumor reductive therapies and antitumor immunity. Oncotarget (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Advances in malignant mesothelioma. N Engl J Med (2005) 8.50
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2004) 5.02
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 5.02
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother (2009) 3.62
Non-small-cell lung cancer. Lancet (2011) 3.45
Immunotherapy and chemotherapy--a practical partnership. Nat Rev Cancer (2005) 3.31
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med (2005) 3.22
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg (2001) 2.54
Regulatory T cells in cancer immunotherapy. Curr Opin Immunol (2014) 2.32
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nat Rev Clin Oncol (2011) 2.15
Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol (2006) 1.81
Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol (2012) 1.71
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol (2013) 1.67
Establishment of a murine model of malignant mesothelioma. Int J Cancer (1992) 1.35
Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys (2005) 1.35
T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res (1999) 1.28
Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One (2009) 1.24
Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol (2008) 1.19
Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother (2008) 1.18
Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol (2012) 1.17
Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One (2013) 1.08
Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene (2013) 1.05
Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res (2005) 1.02
Neoadjuvant vaccination provides superior protection against tumor relapse following surgery compared with adjuvant vaccination. Cancer Res (2009) 0.97
Immunotherapy for colorectal cancer. World J Gastroenterol (2013) 0.94
Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol Cancer Ther (2002) 0.93
How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development. Front Immunol (2013) 0.91
The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene Ther (2001) 0.87
Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8(+) T-cell immunity. Oncoimmunology (2012) 0.87
Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model. J Immunother (2013) 0.83
Vaccines against advanced melanoma. Clin Dermatol (2013) 0.83
Simultaneous immunisation with a Wilms' tumour 1 epitope and its ubiquitin fusions results in enhanced cell mediated immunity and tumour rejection in C57BL/6 mice. Mol Immunol (2012) 0.82
Radiotherapy for mesothelioma. Hematol Oncol Clin North Am (2005) 0.80
Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses. Virology (2010) 0.80
Diffuse malignant mesothelioma of the pleural space and its management. Oncology (Williston Park) (2002) 0.79
Inhibitory influence of the hexapeptidic sequence SLIGRL on influenza A virus infection in mice. J Pharmacol Exp Ther (2012) 0.78
Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother (2010) 0.78
Advances in malignant mesothelioma. N Engl J Med (2005) 8.50
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Malignant mesothelioma. Lancet (2005) 3.93
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet (2011) 3.41
Immunotherapy and chemotherapy--a practical partnership. Nat Rev Cancer (2005) 3.31
Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol (2003) 2.81
Cross-priming in health and disease. Nat Rev Immunol (2010) 2.51
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res (2003) 2.50
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J Exp Med (2010) 2.06
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax (2007) 1.91
Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol (2012) 1.71
Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res (2002) 1.66
IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol (2003) 1.62
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 1.57
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol (2005) 1.48
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res (2010) 1.45
Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int J Cancer (2007) 1.42
Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res (2010) 1.25
Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res (2009) 1.24
Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One (2009) 1.24
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol (2002) 1.21
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest (2007) 1.20
Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol (2008) 1.19
Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci U S A (2011) 1.19
Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother (2008) 1.18
Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol (2009) 1.17
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol (2008) 1.15
Immunogenic anti-cancer chemotherapy as an emerging concept. Curr Opin Immunol (2008) 1.15
The MARS feasibility trial: conclusions not supported by data. Lancet Oncol (2011) 1.13
Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev (2006) 1.12
Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother (2002) 1.12
ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol (2006) 1.11
Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res (2012) 1.11
A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res (2006) 1.11
Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev (2010) 1.10
Comment on "drug discovery: turning the titanic". Sci Transl Med (2014) 1.10
Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res (2006) 1.09
Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One (2013) 1.08
Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res (2012) 1.03
Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res (2005) 1.02
Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol (2004) 1.01
The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol (2012) 1.01
Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med (2009) 1.00
Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best? Lung Cancer (2011) 0.98
Contribution of the immune system to the chemotherapeutic response. Semin Immunopathol (2011) 0.98
Tumor antigen cross-presentation and the dendritic cell: where it all begins? Clin Dev Immunol (2010) 0.97
Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol (2008) 0.97
A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clin Cancer Res (2006) 0.96
Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res (2013) 0.96
Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol (2012) 0.94
Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. J Med Chem (2013) 0.94
Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol (2009) 0.92
Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells. Cancer Immunol Immunother (2008) 0.90
STATing the importance of immune modulation by platinum chemotherapeutics. Oncoimmunology (2012) 0.89
PD-L2 is predominantly expressed by Th2 cells. Mol Immunol (2011) 0.89
Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum. Dis Markers (2013) 0.88
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. J Med Chem (2012) 0.88
CD8alpha+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. Eur J Immunol (2010) 0.88
Acute generalised exanthematous pustulosis mimicking septic shock. Am J Med (2004) 0.87
IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase. Int Immunol (2012) 0.87
Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8(+) T-cell immunity. Oncoimmunology (2012) 0.87
Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening. Lung Cancer (2011) 0.87
Resident CD8(+) and migratory CD103(+) dendritic cells control CD8 T cell immunity during acute influenza infection. PLoS One (2013) 0.86
Soluble mesothelin related protein in mesothelioma. J Thorac Oncol (2006) 0.86
Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. Bioorg Med Chem (2013) 0.85
Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. Eur J Immunol (2014) 0.85
Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation. Oncoimmunology (2012) 0.85
Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am (2005) 0.85
An efficient high-throughput screening method for MYST family acetyltransferases, a new class of epigenetic drug targets. J Biomol Screen (2011) 0.84
Combining immunotherapy with chemotherapy to treat cancer. Discov Med (2005) 0.84
Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model. J Immunother (2013) 0.83
Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer (2013) 0.82
Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors. Cancer Immunol Immunother (2005) 0.81
CD4+ T cells cross-compete for MHC class II-restricted peptide antigen complexes on the surface of antigen presenting cells. Immunol Cell Biol (2004) 0.81